157 related articles for article (PubMed ID: 38644068)
1. Acute coronary syndrome in patients treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants: Proposed management algorithm for the first 48hours.
Salaun A; de Maistre E; Daller M; Sombrun C; Chagué F; Bichat F; Rochette L; Danchin N; Fauchier L; Zeller M; Cottin Y
Arch Cardiovasc Dis; 2024 May; 117(5):351-357. PubMed ID: 38644068
[TBL] [Abstract][Full Text] [Related]
2. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
[TBL] [Abstract][Full Text] [Related]
3. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
4. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial.
Dillinger JG; Ducrocq G; Elbez Y; Cohen M; Bode C; Pollack C; Nicolau JC; Henry P; Kedev S; Wiviott SD; Sabatine MS; Mehta SR; Steg PG
Circ Cardiovasc Interv; 2018 Jun; 11(6):e006084. PubMed ID: 29895599
[TBL] [Abstract][Full Text] [Related]
5. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence.
Martin AC; Godier A; Narayanan K; Smadja DM; Marijon E
Circulation; 2018 Aug; 138(6):627-633. PubMed ID: 30354610
[TBL] [Abstract][Full Text] [Related]
6. Novel Oral Anticoagulants Following Percutaneous Coronary Intervention.
Abadie BQ; Cannon CP; Cavender MA
Circ Cardiovasc Interv; 2020 Jul; 13(7):e008465. PubMed ID: 32673510
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
Angiolillo DJ; Goodman SG; Bhatt DL; Eikelboom JW; Price MJ; Moliterno DJ; Cannon CP; Tanguay JF; Granger CB; Mauri L; Holmes DR; Gibson CM; Faxon DP
Circulation; 2018 Jul; 138(5):527-536. PubMed ID: 30571525
[TBL] [Abstract][Full Text] [Related]
8. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview.
Rubboli A; Faxon DP; Juhani Airaksinen KE; Schlitt A; Marín F; Bhatt DL; Lip GY
Thromb Haemost; 2014 Dec; 112(6):1080-7. PubMed ID: 25298351
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
[TBL] [Abstract][Full Text] [Related]
10. [Bleeding risk and perioperative management of patients anticoagulated with vitamin K antagnosists].
Angelo M; Stockner I; Wiedermann CJ
Wien Med Wochenschr; 2008; 158(21-22):615-20. PubMed ID: 19052707
[TBL] [Abstract][Full Text] [Related]
11. Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
Spinthakis N; Farag M; Akhtar Z; Gorog DA
Curr Vasc Pharmacol; 2018; 16(5):427-436. PubMed ID: 29345587
[TBL] [Abstract][Full Text] [Related]
12. Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
Beinema MJ; van der Meer FJ; Brouwers JR; Rosendaal FR
J Thromb Haemost; 2016 Mar; 14(3):479-84. PubMed ID: 26712475
[TBL] [Abstract][Full Text] [Related]
13. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.
Pritchard ER; Murillo JR; Putney D; Hobaugh EC
J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375
[TBL] [Abstract][Full Text] [Related]
14. Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists?
Steib A; Barre J; Mertes M; Morel MH; Nathan N; Ozier Y; Treger M; Samama CM
J Thromb Haemost; 2010 Mar; 8(3):499-503. PubMed ID: 19912513
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
Lopes RD; Heizer G; Aronson R; Vora AN; Massaro T; Mehran R; Goodman SG; Windecker S; Darius H; Li J; Averkov O; Bahit MC; Berwanger O; Budaj A; Hijazi Z; Parkhomenko A; Sinnaeve P; Storey RF; Thiele H; Vinereanu D; Granger CB; Alexander JH;
N Engl J Med; 2019 Apr; 380(16):1509-1524. PubMed ID: 30883055
[TBL] [Abstract][Full Text] [Related]
16. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
17. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
Lopes RD; Vora AN; Liaw D; Granger CB; Darius H; Goodman SG; Mehran R; Windecker S; Alexander JH
Am Heart J; 2018 Jun; 200():17-23. PubMed ID: 29898844
[TBL] [Abstract][Full Text] [Related]
18. Use of oral anticoagulants in complex clinical situations with atrial fibrillation.
Gullón A; Sánchez Fuentes D; López-de-Sá E; Martí-Almor J; Barón-Esquivias G; Jiménez López J; Del Mar Contreras Muruaga M; Suárez Fernández C
Med Clin (Barc); 2018 Jun; 150 Suppl 1():8-24. PubMed ID: 30502871
[TBL] [Abstract][Full Text] [Related]
19. Vitamin K to reverse the anticoagulant effect of vitamin K antagonists: can you teach an old dog new tricks?
Douketis JD; Spyropoulos AC
J Thromb Haemost; 2010 Mar; 8(3):496-8. PubMed ID: 20040039
[No Abstract] [Full Text] [Related]
20. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
